PHOENIX, ARIZ, September 17, 2024 – Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis & Dionne Professor of Neurological Surgery, has been recognized as the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. He will receive the award at the 20th Annual AZBio Awards on Wednesday, September 18 at the Phoenix Convention Center. Dr. Sanai is being honored for his pioneering spirit and commitment to push beyond the status quo to discover new therapies for his brain tumor patients. Continue reading
Category Archives: AZBio News
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
PHOENIX and FRIENDSWOOD, TX – Sept. 16, 2024 – The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, presented by AZBio, recognizes Oelschlager for her outstanding leadership that has contributed significantly to the progression of the bioscience industry in Arizona.Continue reading
C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development
WASHINGTON, Sept. 12, 2024 — Critical Path Institute (C-Path) successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024, at the Washington Marriott at Metro Center in Washington, D.C. This landmark event brought together industry leaders, regulatory agencies, academic experts, and patient advocacy groups, all dedicated to advancing drug development and regulatory science for rare diseases. Continue reading
Macula Vision Systems Shines in Prestigious Global Competitions, State Accelerator and Bioscience Entrepreneurship Program
Tucson, AZ — University of Arizona Center for Innovation (UACI) is proud to announce that Macula Vision Systems, a pioneer in clinical microscopy, continues to gain momentum as it advances in both national and international stages of the life sciences industry. Macula Vision Systems is based out of UACI at Oro Valley, Arizona – an incubator focused on supporting bioscience startups by providing specialized lab space and tailored business development programming. In recent and upcoming weeks, the company proudly stands out by participating in prestigious programs and pitch competitions, highlighting its groundbreaking advancements in high-throughput imaging and automated interpretation technologies.Continue reading
GT Medical Technologies, Inc. Secures $35 Million Venture Loan Facility from Horizon Technology Finance
TEMPE, Ariz., Sept. 12, 2024 /PRNewswire/ — GT Medical Technologies, Inc. (“GT MedTech” or the “Company”), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced it has secured a $35 million venture loan facility, of which $15 million has been initially funded from Horizon Technology Finance Corporation (NASDAQ: HRZN), an affiliate of Monroe Capital.Continue reading
TGen launches Center for Spatial Multi-Omics (COSMO): A Service Center dedicated to transforming biomedical research through spatial biology
PHOENIX, AZ (September 11, 2024) – The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of the Center for Spatial Multi-Omics (COSMO), a service center dedicated to transforming biomedical research through spatial biology. COSMO offers an unparalleled suite of services designed to help scientists visualize and map molecular data at the single-cell level directly within tissues.Continue reading
FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases
- U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers’ trials
- Letter is latest milestone in the journey of the biomarker, discovered in 2023, to transform drug development focused on synuclein pathology — a biological hallmark of Parkinson’s, Dementia with Lewy Bodies and related neurodegenerative conditions
- FDA notes critical role of the Parkinson’s Progression Markers Initiative in generating and validating data and studies that made this landmark step forward possible
BIO5 Institute’s Kelle Hyland honored as 2024 AZBio Bioscience Educator of the Year
An integral part of the BIO5 Institute’s KEYS Research Internship program for the past 8 years, Kelle Hyland has been recognized for her extraordinary leadership and dedication by the Arizona Bioindustry Association.Continue reading
AZBioPEERS Video: Preparing for Investor Success
This AZBioPEERS webinar is presented by Richard Kovacik, JD, MBA, Managing Director of the Healthcare Growth Group. The program is designed to equip life science startups with an overview of the most important knowledge and considerations needed to attract and engage investors.Continue reading